A Pilot Study on the Treatment of Posterior Cheek Enlargement in HIV+ Patients With Botulinum Toxin A

Scali, Christina; Carruthers, Alastair; Malpas, Dean; Humphrey, Shannon

doi:10.1097/dss.0000000000000510

Cited by 7 publications

(7 citation statements)

References 23 publications

(30 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Without treatment, hypertrophic parotid glands can affect the contour and appearance of the face, which can lead to psychological issues. 11 Our prospective single-arm trial demonstrated that botulinum toxin type A injection was efficacious in improving parotid gland hypertrophy and the lateral contours of the face.…”

Section: Discussionmentioning

confidence: 83%

“…Without treatment, hypertrophic parotid glands can affect the contour and appearance of the face, which can lead to psychological issues. 11 Our prospective We selected change in size of the superficial lobe of the parotid gland (rather than the total thickness) as the primary outcome because of differences in parotid gland morphology between individual patients, because measurement of the deep boundary is not straightforward, and because deep-echo attenuation will lead to greater measuring error. 17 Ultrasound was used to measure the distance from the superficial lateral wall of the retromandibular vein to the superficial lobe of the parotid gland capsule.…”

Section: Discussionmentioning

confidence: 99%

“…10 In recent years, several studies have demonstrated that injection of botulinum toxin is efficacious for the treatment of hypersalivation caused by diseases such as acquired immunodeficiency syndrome or Parkinson disease. 11,12 Studies have found that botulinum toxin can reduce saliva secretion but also reduce the volume of hypertrophic parotid glands. Botulinum toxin reduces the volume of hypertrophic gland cells, thereby reducing parotid gland size, but the underlying mechanism is unclear.…”

Section: Ementioning

confidence: 99%

See 2 more Smart Citations

Efficacy and Safety of Botulinum Toxin Type A in the Treatment of Benign Parotid Hypertrophy: a Prospective, Single-arm Clinical Trial

Zong

Chen

Liu

et al. 2022

Plastic &Amp; Reconstructive Surgery

View full text Add to dashboard Cite

Background: Benign parotid hypertrophy makes the earlobe area appear swollen and weakens the lateral facial contour and aesthetics. Efficacious treatment for benign parotid hypertrophy is not available. The authors evaluated the efficacy and safety of botulinum toxin type A for benign parotid hypertrophy treatment. Methods: Thirty-six participants with benign parotid hypertrophy were enrolled and treated with botulinum toxin type A injection. After 6 months of follow-up, changes in the thickness and length of the superficial lobe of the parotid gland were assessed. Analyses of patient subgroups and image analyses were also undertaken to assess improvement. Results: Thirty-three participants completed this study. Superficial lobe of the parotid gland thickness was reduced significantly after botulinum toxin type A injection, but the longitudinal diameter of the parotid gland was not changed significantly (p < 0.001 and p = 0.146, respectively). Subgroup analyses showed that the degree of parotid gland hypertrophy affected treatment efficacy and degree of improvement, but age and sex did not (p < 0.001, p = 0.137, and p = 0.138, respectively). Image analyses showed improvement in the facial contour (p < 0.05). Serious adverse reactions or complications were not observed. Conclusion: Botulinum toxin type A can be used to treat benign parotid hypertrophy, reduce parotid gland volume, and improve the facial contour. CLINICAL QUESTION/LEVEL OF EVIDENCE: Therapeutic, IV.

show abstract

Section: Discussionmentioning

confidence: 83%

Section: Discussionmentioning

confidence: 99%

Section: Ementioning

confidence: 99%

See 1 more Smart Citation

Efficacy and Safety of Botulinum Toxin Type A in the Treatment of Benign Parotid Hypertrophy: a Prospective, Single-arm Clinical Trial

Zong

Chen

Liu

et al. 2022

Plastic &Amp; Reconstructive Surgery

View full text Add to dashboard Cite

show abstract

“…Human immunodeficiency virus could also cause unilateral or bilateral posterior cheek enlargement with lymphatic infiltrates or hyperplastic intraparotid lymph nodes in gland tissue. 18 These findings can be treated with intraglandular BTX-A injection. Inflammatory diseases such as Sjögren syndrome and sarcoidosis and neoplastic disease also affect the parotid gland.…”

Section: Discussionmentioning

confidence: 99%

The Volumetric effect of Botulinum Toxin Type A Injection on Parotid Gland: A Prospective Randomized Controlled Trial

Jeong

Hong

Ahn³

et al. 2023

Plastic &Amp; Reconstructive Surgery

View full text Add to dashboard Cite

Background: Botulinum neurotoxin type A (BTX-A) to the masseter muscle is a useful tool for the aesthetic narrowing of the width of the lower face. The administration of BTX-A to visible parotid glands is also effective to reduce lower facial width. However, no studies have quantitatively analyzed the effect of BTX-A on the parotid glands. Methods: The purpose of this study was to confirm the impact of BTX-A injection on the parotid gland and to suggest the effective dosage of BTX-A in facial slimming. This study was conducted by selecting patients who desired facial slimming from among patients who required surgery for a facial bone fracture. Patients undergoing BTX-A injection were randomized to high-dose, low-dose, and placebo groups, and different doses of BTX-A for each group were injected into both parotid glands during facial bone surgery. Results: A total of 30 patients were enrolled in this study. Ten patients in the high-dose group, eight in the low-dose group, and nine in the control group completed the clinical trial. There were significant changes in both the high- and low-dose groups compared with the control group (P < 0.001, P < 0.001), and in interaction of time and group (P < 0.001). Volume recovery after 3 months was found in 7.6% in the high-dose group and in 4.8% in the low-dose group. Conclusion: BTX-A injection into parotid glands can be an effective treatment option in managing salivary gland enlargement for lower face contouring. CLINICAL QUESTION/LEVEL OF EVIDENCE: Therapeutic, II.

show abstract

“…This effect could be beneficial in reducing parotid gland size for patients with parotid gland hypertrophy. 21,22 However, in rare cases, this could also cause xerostomia. 18 The average width of the masseter muscle was 33.62 mm; however, the average primary horizontal spreading was 15.60 mm.…”

Section: Discussionmentioning

confidence: 99%

A Cadaveric Study of Dye Spreading: Determining the Ideal Injection Pattern for Masseter Hypertrophy

Sermswan

Tansatit

Meevassana

et al. 2021

View full text Add to dashboard Cite

BACKGROUND Masseter hypertrophy is the main cause of an asymmetrical and squared lower facial contour in the Asian community. Botulinum toxin injection technique is crucial to treat this condition. OBJECTIVE To improve injection techniques for masseter hypertrophy by elucidating the distribution of the injections within the masseter. METHODS Thirty masseter muscles were divided into 6 groups of 5 muscles each. Each group received one 0.2- or 0.3-mL injection at Point A, B, or C according to a three-point technique. Muscle dimensions and dye of the primary and secondary dye spreading were measured. RESULTS The average muscle length, width, and thickness were 69.87, 33.50, and 11.23 mm, respectively. The average primary longitudinal and horizontal spreading was 36.56 and 15.60 mm, respectively. No statistically significant difference was found between 0.2- and 0.3-mL injections at each point. CONCLUSION The three-point technique best fits in the safe zone and should be the standard injection technique for masseter hypertrophy. Injection at Points B and C may create secondary spreading that affect the risorius muscle and the parotid gland which are the cause of asymmetrical smiling and xerostomia, respectively. The dosage should be adjusted according to the muscle volume and not only the thickness.

show abstract

A Pilot Study on the Treatment of Posterior Cheek Enlargement in HIV+ Patients With Botulinum Toxin A

Abstract: Botulinum toxin A may be a less invasive treatment of posterior cheek enlargement in HIV+ patients, with advantages of a good result that is long lasting with good tolerability and minimal risk.

Cited by 7 publications

References 23 publications

Efficacy and Safety of Botulinum Toxin Type A in the Treatment of Benign Parotid Hypertrophy: a Prospective, Single-arm Clinical Trial

Efficacy and Safety of Botulinum Toxin Type A in the Treatment of Benign Parotid Hypertrophy: a Prospective, Single-arm Clinical Trial

The Volumetric effect of Botulinum Toxin Type A Injection on Parotid Gland: A Prospective Randomized Controlled Trial

A Cadaveric Study of Dye Spreading: Determining the Ideal Injection Pattern for Masseter Hypertrophy

Contact Info

Product

Resources

About